MX2020012534A - Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos. - Google Patents

Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos.

Info

Publication number
MX2020012534A
MX2020012534A MX2020012534A MX2020012534A MX2020012534A MX 2020012534 A MX2020012534 A MX 2020012534A MX 2020012534 A MX2020012534 A MX 2020012534A MX 2020012534 A MX2020012534 A MX 2020012534A MX 2020012534 A MX2020012534 A MX 2020012534A
Authority
MX
Mexico
Prior art keywords
agi
treatment
combined
solid tumors
checkpoint inhibitor
Prior art date
Application number
MX2020012534A
Other languages
English (en)
Inventor
Irit Carmi Levy
Original Assignee
Biolinerx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolinerx Ltd filed Critical Biolinerx Ltd
Publication of MX2020012534A publication Critical patent/MX2020012534A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe un método para tratar un tumor en un sujeto. El método comprende administrar al sujeto una cantidad terapéuticamente eficaz de: i) pembrolizumab; y ii) un lípido que tiene una fórmula estructural como se ilustra en la Figura 1 (AGI-134).
MX2020012534A 2018-05-27 2019-05-27 Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos. MX2020012534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676999P 2018-05-27 2018-05-27
PCT/IL2019/050601 WO2019229745A1 (en) 2018-05-27 2019-05-27 Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
MX2020012534A true MX2020012534A (es) 2021-04-28

Family

ID=66821287

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012534A MX2020012534A (es) 2018-05-27 2019-05-27 Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos.

Country Status (10)

Country Link
US (1) US20210121491A1 (es)
EP (1) EP3801614A1 (es)
JP (1) JP2021525233A (es)
CN (1) CN112384242A (es)
AU (1) AU2019277908A1 (es)
BR (1) BR112020023955A2 (es)
CA (1) CA3099383A1 (es)
IL (1) IL279000A (es)
MX (1) MX2020012534A (es)
WO (1) WO2019229745A1 (es)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EA013183B1 (ru) 2004-03-22 2010-02-26 Коуд Байотек Лимитид Синтетические молекулярные конструкции
US7820628B2 (en) 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
WO2015170121A1 (en) * 2014-05-09 2015-11-12 Agalimmune Limited Glycolipid containing compositions for use in the treatment of tumours

Also Published As

Publication number Publication date
US20210121491A1 (en) 2021-04-29
CN112384242A (zh) 2021-02-19
JP2021525233A (ja) 2021-09-24
CA3099383A1 (en) 2019-12-05
IL279000A (en) 2021-01-31
AU2019277908A1 (en) 2021-01-07
WO2019229745A1 (en) 2019-12-05
BR112020023955A2 (pt) 2021-02-23
EP3801614A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2023014028A (es) Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
NZ726366A (en) Syk inhibitors
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
WO2023172629A3 (en) Anticancer maleimide derivatives for use with immune checkpoint blockade
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2020012534A (es) Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.